The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Chronic Ankle Instability
NCT07728526, Not applicable, Recruiting, Bahçeşehir University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Chronic Ankle Instability | ClinicalTrials.gov |
| NCT number | NCT07728526 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Bahçeşehir University | ClinicalTrials.gov |
| Conditions | Ankle Sprains, Ankle Sprain Strain, Ankle Inversion Sprain | ClinicalTrials.gov |
| Interventions | Postural Stabilization Training, Vestibulo-Ocular Reflex Exercise in addition to Postural Stabilization Training | ClinicalTrials.gov |
| First posted | 2026-07-27 | ClinicalTrials.gov |
| Last updated | 2026-10-23 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Y Balance Test | baseline, 6 weeks after baseline, and 10-week after baseline | The Y-Balance Test will be used to assess dynamic postural control. Participants will perform the test barefoot, standing on the test limb with hands on the hips, and will reach in the anterior, posteromedial, and posterolateral directions with the free limb. Invalid trials, including loss of balance, movement of the stance foot, or removal of the hands from the hips, will be repeated. Reach distances will be recorded in centimeters, normalized to limb length, and a composite score will be calculated. | ClinicalTrials.gov |
| Secondary | Cumberland Ankle Instability Tool | baseline, 6 weeks after baseline, and 10-week after baseline | The Cumberland Ankle Instability Tool is a 9-item questionnaire used to evaluate perceived ankle instability and functional limitations. The total score ranges from 0 to 30, with lower scores indicating greater ankle instability. A score of 24 or lower is considered consistent with functional ankle instability | ClinicalTrials.gov |
| Secondary | Single-Leg Stance + Number / Word Sequence Task | baseline, 6 weeks after baseline, and 10-week after baseline | This task will assess static balance under cognitive load. Participants will stand on the affected limb on a foam pad and perform a backward number or word sequence task. In the first 10 seconds, the researcher will read six random items; participants must repeat them in reverse order within the next 10 seconds while maintaining balance. Each trial will last 20 seconds. Postural errors include removing hands from the hips, touching the ground with the non-stance foot, moving or hopping on the stance foot, hip flexion or abduction \>30°, limb contact, loss of balance, or failure to maintain the position for \>5 seconds. Each error scores 1 point, up to 10 per trial. One cognitive error is recorded for incorrect order, incomplete recall, or no response within 10 seconds. The total score is the sum of postural and cognitive errors; higher scores indicate poorer performance. After one practice trial, three trials will be recorded, and the mean total error score will be used for analysis. | ClinicalTrials.gov |
| Secondary | Side Hop Test + Pinhole Glasses | baseline, 6 weeks after baseline, and 10-week after baseline | This test will assess hopping performance under visual constraint. Participants will stand on the affected limb and hop laterally and medially over two parallel lines placed 30 cm apart. Before testing, they will complete 3-4 submaximal practice repetitions without visual constraint. During testing, participants will wear pinhole glasses and complete the task as quickly as possible. One repetition is defined as hopping from the outside of one line to the outside of the opposite line and back to the starting side. The time required to complete 10 round-trip hops will be recorded in seconds. Two trials will be performed with a 60-second rest interval, and the shortest time will be used for analysis. A trial will be repeated if the contralateral limb touches the ground, the participant steps on a line, double-limb contact occurs, or the hopping sequence is interrupted. | ClinicalTrials.gov |
| Secondary | Figure-of-Eight Hop Test + Backward Counting Task | baseline, 6 weeks after baseline, and 10-week after baseline | The Figure-of-Eight Hop Test with backward counting will assess hopping performance under cognitive load. Participants will hop on the affected limb around two cones placed 5 m apart, completing the figure-of-eight pattern twice as quickly as possible. Before testing, they will walk through the course and complete one submaximal hopping trial without the cognitive task. During testing, participants will count backward by sevens from a number between 200 and 250; numbers ending in 7 or 0 will be excluded. They will perform both tasks simultaneously without prioritizing either. After a cognitive error, the researcher will provide the correct response and the participant will continue. A trial will be repeated after contralateral foot contact, double-limb contact, cone contact or displacement, course deviation, pattern disruption, or balance loss. Two trials will be performed with 60-s rest. The shortest completion time and number of correct cognitive responses will be recorded. | ClinicalTrials.gov |
| Secondary | Stroop Test | baseline, 6 weeks after baseline, and 10-week after baseline | This test will assess selective attention and inhibitory control and will be administered in a seated position after a brief practice trial. Participants will complete three conditions: color naming, word reading, and incongruent color-word naming. In the incongruent condition, they will name the ink color while inhibiting the tendency to read the word; this condition will serve as the primary measure of inhibitory control and interference resolution. Completion time will be recorded in seconds for each condition. Errors and spontaneous corrections will also be recorded for the incongruent condition. Interference resistance will be calculated as incongruent ink-color naming time minus word reading time. Outcomes will include color naming time, word reading time, incongruent condition time, interference resistance time, errors, and spontaneous corrections. | ClinicalTrials.gov |
| Secondary | Foot and Ankle Ability Measure (FAAM) | baseline, 6 weeks after baseline, and 10-week after baseline | The Foot and Ankle Ability Measure Turkish Version (FAAM-T) will be used to evaluate postural stability and foot/ankle-related functional ability following chronic ankle instability and lateral ankle sprain. The FAAM consists of 29 items and includes two subscales: the Activities of Daily Living subscale (FAAM-ADL, 21 items) and the Sports subscale (FAAM-S, 8 items). The Sports subscale is specifically designed to assess sport-related function and complex motor tasks and is widely used as a self-reported outcome measure in athletic populations. Scores are expressed as a percentage, with lower scores indicating greater sport-related functional limitation. | ClinicalTrials.gov |
| Secondary | Weight-Bearing Lunge Test | baseline, 6 weeks after baseline, and 10-week after baseline | The Weight-Bearing Lunge Test will be used to assess ankle dorsiflexion range of motion in a weight-bearing position. The maximum distance at which the knee can touch the wall without heel lift will be measured in centimeters. A dorsiflexion distance on the affected side that is ≥2.5 cm less than the unaffected side will be considered indicative of dorsiflexion limitation. | ClinicalTrials.gov |
| Secondary | Dynamic Visual Acuity Test | baseline, 6 weeks after baseline, and 10-week after baseline | The Dynamic Visual Acuity Test will be used to assess the functional status of the vestibulo-ocular reflex (VOR). Static visual acuity (SVA) and dynamic visual acuity (DVA) during active head movements will be measured, and the difference between these two values will be used as an indicator of VOR function. For both measurements, the smallest line that can be read with at least 50% accuracy will be recorded. The change in the SVA-DVA difference will be reported after the intervention | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)